| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IGLV3-21 |
| Uniprot No | P80748 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-233aa |
| 氨基酸序列 | MAWTVLLLGLLSHCTVSVTSYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVMVVYDDSDRPSGIPERLSGSNSGNTATLTISRVEAGDEADYYCQVWDSTSNHYVFGTGTKVSVLSQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS |
| 分子量 | 51.3 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人IGLV3-21蛋白的3篇参考文献及相关摘要概括：
---
1. **文献名称**: *Structural and Functional Characterization of Recombinant Human IGLV3-21 Protein in B-Cell Malignancies*
**作者**: Müller, A. et al.
**摘要**: 本研究解析了重组人IGLV3-21蛋白的结构，并探讨其在B细胞恶性肿瘤(如慢性淋巴细胞白血病)中的异常表达。实验表明，IGLV3-21通过与特定细胞表面受体相互作用，可能促进肿瘤细胞存活。
---
2. **文献名称**: *Expression and Purification of Recombinant IGLV3-21 in Escherichia coli for Diagnostic Applications*
**作者**: Chen, L. & Zhang, W.
**摘要**: 作者优化了IGLV3-21蛋白在大肠杆菌中的重组表达与纯化工艺，开发了高效制备方法。该蛋白被应用于开发自身免疫疾病的血清学检测试剂盒，展现出高特异性。
---
3. **文献名称**: *IGLV3-21 R110 Mutation in Multiple Myeloma: Role of Recombinant Protein in Pathogenesis*
**作者**: Rossi, D. et al.
**摘要**: 研究聚焦于IGLV3-21基因R110突变体重组蛋白的功能，发现其增强与轻链淀粉样变性相关的异常蛋白聚集倾向，为多发性骨髓瘤的分子机制提供了新见解。
---
**备注**：以上文献信息为模拟示例，实际文献需通过PubMed或Web of Science查询(可尝试关键词：IGLV3-21 recombinant/ monoclonal antibody/ B-cell malignancy)。部分研究可能与其轻链在抗体工程或疾病生物标志物中的作用相关。
Recombinant human IGLV3-21 protein is derived from the immunoglobulin lambda variable 3-21 (IGLV3-21) gene, which encodes a portion of the light chain of antibodies. Immunoglobulin light chains, including lambda chains like IGLV3-21. pair with heavy chains to form antigen-binding regions critical for antibody specificity. The IGLV3-21 gene is part of the immunoglobulin variable gene repertoire, contributing to the diversity of adaptive immune responses. Notably, a specific somatic mutation (R66 substitution) in IGLV3-21 has been linked to clinically aggressive forms of B-cell malignancies, such as chronic lymphocytic leukemia (CLL), particularly when co-expressed with receptor tyrosine kinase ROR1.
Recombinant production of IGLV3-21 involves cloning and expressing the gene in host systems (e.g., bacteria or mammalian cells) to generate purified protein for research or therapeutic applications. The protein retains antigen-binding properties, making it valuable for studying B-cell receptor (BCR) signaling, antibody-antigen interactions, and pathological mechanisms in B-cell disorders. It is also explored as a potential diagnostic marker or therapeutic target. In drug development, recombinant IGLV3-21 may serve as a component of engineered antibodies or CAR-T therapies targeting malignant B cells. Its study enhances understanding of immune dysregulation and supports precision medicine approaches in oncology and immunology.
×
